Jacob T. Cain, Ph.D.
Affiliations: | 2013 | Biology | The University of North Dakota, Grand Forks, ND, United States |
Area:
Human Development, Neuroscience Biology, General BiologyGoogle:
"Jacob Cain"Mean distance: 53433
Parents
Sign in to add mentor| Jill M. Weimer | grad student | |||
| Diane C. Darland | grad student | 2013 | University of North Dakota | |
| (Vascular endothelial growth factor in cortical development.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Johnson TB, Brudvig JJ, Likhite S, et al. (2023) Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease. Frontiers in Genetics. 14: 1118649 |
| Rechtzigel MJ, Meyerink BL, Leppert H, et al. (2022) Transmembrane Batten Disease Proteins Interact With a Shared Network of Vesicle Sorting Proteins, Impacting Their Synaptic Enrichment. Frontiers in Neuroscience. 16: 834780 |
| Lu CL, Ortmeier S, Brudvig J, et al. (2021) Collagen has a unique SEC24 preference for efficient export from the endoplasmic reticulum. Traffic (Copenhagen, Denmark) |
| Johnson TB, White KA, Brudvig JJ, et al. (2020) AAV9 Gene Therapy Increases Lifespan and Treats Pathological and Behavioral Abnormalities in a Mouse Model of CLN8-Batten Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Johnson TB, Mechels K, Anderson RH, et al. (2020) Author Correction: Characterization of a recurrent missense mutation in the forkhead DNA-binding domain of FOXP1. Scientific Reports. 10: 6635 |
| Johnson TB, Brudvig JJ, Lehtimäki KK, et al. (2020) A multimodal approach to identify clinically relevant biomarkers to comprehensively monitor disease progression in a mouse model of pediatric neurodegenerative disease. Progress in Neurobiology. 101789 |
| Oksman J, Lehtimäki K, Bragge T, et al. (2020) Principal component analysis (PCA) based data fusion approach for a mouse model of CLN8 Batten disease Molecular Genetics and Metabolism. 129: S119 |
| Lehtimäki K, Bragge T, Rytkönen J, et al. (2020) Longitudinal characterization of the mouse model of CLN8 Batten disease fine motor performance, retinal degeneration, brain pathology, and metabolic changes Molecular Genetics and Metabolism. 129: S97 |
| White KA, Cain JT, Magee H, et al. (2019) Modulation of CRMP2 via ()-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease. Health Psychology and Behavioral Medicine. 3: NS20190001 |
| Cain JT, Likhite S, White KA, et al. (2019) Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy |